CompletedPhase 2NCT00193973

Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma

Studying Lymphoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Trans Tasman Radiation Oncology Group
Principal Investigator: Peter O'Brien, FRANZCR
Newcastle Mater Misericordiae Hospital
Intervention: Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C(drug)
Enrollment: 20 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2001 – 2013

Study locations (15)

The Canberra Hospital, Garran, Australian Capital Territory, Australia
Calvary Mater Newcastle, Newcastle, New South Wales, Australia
Prince of Wales Hospital, Randwick, New South Wales, Australia
Westmead Hospital, Wentworthville, New South Wales, Australia
Illawarra Cancer Care Centre, Wollongong, New South Wales, Australia
Royal Brisbane Hospital, Herston, Queensland, Australia
Mater QRI, South Brisbane, Queensland, Australia
Premion - Tugun, Tugun, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Andrew Love Cancer Centre, Geelong Hospital, Geelong, Victoria, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
Auckland Hospital, Auckland, New Zealand
Christchurch Hospital, Christchurch, New Zealand

Collaborators

Australasian Leukaemia and Lymphoma Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00193973 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma →

← Back to all trials